erucylphospho-n,n,n-trimethylpropylammonium profile

erucylphospho-N,N,N-trimethylpropylammonium: an antineoplastic agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10323834
SCHEMBL ID	21094307
MeSH ID	M0447838

Synonym
erufosine
erucylphospho-n,n,n-trimethylpropylammonium
erucylphosphohomocholine
SCHEMBL21094307
unii-w52c2ekx3f
((z)-docos-13-enyl) 3-(trimethyl-lambda5-azanyl)propyl hydrogen phosphate
1-propanaminium, 3-((((13z)-13-docosen-1-yloxy)hydroxyphosphinyl)oxy)-n,n,n-trimethyl-, inner salt
((z)-docos-13-enyl) 3-(trimethyl-$l^5-azanyl)propyl hydrogen phosphate
erpc 3
202867-33-2
erpc-3
W52C2EKX3F ,

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" Erufosine was not toxic to normal HPCs of murine or human origin and even stimulated progenitors from human umbilical cord blood to form granulocyte/macrophage colonies."	( Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Berger, MR; Georgiev, KD; Konstantinov, SM; Pilicheva, BA; Todorov, PT; Yosifov, DY; Zaharieva, MM, 2011)	1.81
"Erufosine was less toxic to human and mouse bone marrow cells than perifosine, miltefosine, and edelfosine and was equally toxic to human and mouse CFU-GM."	( Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells. Bagley, RG; Kurtzberg, L; Rouleau, C; Teicher, BA; Yao, M, 2011)	0.37

Compound-Compound Interactions

Excerpt	Reference	Relevance
" The latter agents, however, exerted an additive cytotoxicity in combination with ErPC3 as revealed by isobologram analysis and combination index, although results are uneven for idarubicine."	( Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Braess, J; Eibl, H; Fiegl, M; Hiddemann, W; Juergens, M; Lindner, LH, 2008)	0.35
" Our investigations establish the basis for a future efficacy testing of Erufosine in xenograft tumor models in nude mice alone and in combination with chemo- or radiotherapy."	( Pharmacokinetics and biodistribution of Erufosine in nude mice--implications for combination with radiotherapy. Bamberg, M; Belka, C; Eibl, HJ; Henke, G; Jendrossek, V; Lindner, LH; Müller, AC; Vogeser, M; Wachholz, K; Wörner, J, 2009)	0.35
" Furthermore, an increased radiation-induced growth delay of T98G xenograft tumours was observed when fractionated irradiation was combined with short-term Erufosine-treatment."	( Effects of ionizing radiation in combination with Erufosine on T98G glioblastoma xenograft tumours: a study in NMRI nu/nu mice. Bamberg, M; Belka, C; Budach, W; Eibl, H; Henke, G; Jendrossek, V; Lindner, LH; Meier, V, 2012)	0.38
"We conclude that short-term treatment with Erufosine is not sufficient to significantly improve local control in combination with radiotherapy in T98G glioblastoma xenograft tumours."	( Effects of ionizing radiation in combination with Erufosine on T98G glioblastoma xenograft tumours: a study in NMRI nu/nu mice. Bamberg, M; Belka, C; Budach, W; Eibl, H; Henke, G; Jendrossek, V; Lindner, LH; Meier, V, 2012)	0.38

Bioavailability

Excerpt	Reference	Relevance
" In view of a possible combination of Erufosine and radiotherapy in vivo we determined the pharmacokinetics and bioavailability as well as the tolerability of Erufosine in nude mice."	( Pharmacokinetics and biodistribution of Erufosine in nude mice--implications for combination with radiotherapy. Bamberg, M; Belka, C; Eibl, HJ; Henke, G; Jendrossek, V; Lindner, LH; Müller, AC; Vogeser, M; Wachholz, K; Wörner, J, 2009)	0.35

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	10 (27.78)	29.6817
2010's	21 (58.33)	24.3611
2020's	5 (13.89)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (2.78%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	35 (97.22%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	4.45	6	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
edelfosine edelfosine: RN given refers to parent cpd. edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.. 1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.	3.18	1	glycerophosphocholine
dapi DAPI: RN given refers to parent cpd.	2.05	1	indoles	fluorochrome
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	4.18	4	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.05	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.03	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
methylnitrosourea Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.	2.07	1	N-nitrosoureas	alkylating agent; carcinogenic agent; mutagen; teratogenic agent
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	2.04	1	dihydrogen
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	2.02	1
paxilline paxilline: structure given in first source; RN given refers to (2R-(2alpha,4bbeta,6aalpha,12bbeta,12calpha,14abeta))-isomer. paxilline : An indole diterpene alkaloid with formula C27H33NO4 isolated from Penicillium paxilli. It is a potent inhibitor of large conductance Ca2(+)- and voltage-activated K(+) (BK)-type channels.	2.1	1	diterpene alkaloid; enone; organic heterohexacyclic compound; terpenoid indole alkaloid; tertiary alcohol	anticonvulsant; Aspergillus metabolite; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; genotoxin; geroprotector; mycotoxin; Penicillium metabolite; potassium channel blocker
perifosine [no description available]	3.9	3	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.1	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
erucylphosphocholine erucylphosphocholine: structure given in first source	3.56	2
abt-737 [no description available]	2.66	2	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
oligonucleotides [no description available]	2.03	1
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.66	2

Condition	Relationship Strength	Studies
Androgen-Independent Prostatic Cancer [description not available]	2.66	2
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	2.66	2
Carcinoma, Non-Small Cell Lung [description not available]	2.41	1
Cancer of Lung [description not available]	2.41	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.41	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.41	1
Black Fever [description not available]	2.6	1
Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.	2.6	1
Bone Cancer [description not available]	2.47	2
Breast Cancer [description not available]	3.17	5
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.47	2
Breast Neoplasms Tumors or cancer of the human BREAST.	3.17	5
Extravascular Hemolysis [description not available]	2.25	1
Benign Neoplasms [description not available]	3.46	2
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.25	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.46	2
Carcinoma, Epidermoid [description not available]	2.81	3
Cancer of Mouth [description not available]	2.81	3
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.81	3
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.81	3
Benign Neoplasms, Brain [description not available]	2.48	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.46	2
Astrocytoma, Grade IV [description not available]	2.78	3
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.48	2
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.78	3
Cancer of Skin [description not available]	2.1	1
Cutaneous T-Cell Lymphoma [description not available]	2.1	1
Skin Neoplasms Tumors or cancer of the SKIN.	2.1	1
Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.	2.1	1
Capsule Opacification Clouding or loss of transparency of the posterior lens capsule, usually following CATARACT extraction.	2.51	2
Colorectal Cancer [description not available]	2.1	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.1	1
Cancer of Prostate [description not available]	2.48	2
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.48	2
Leukemia, Lymphocytic, T Cell [description not available]	2.1	1
Leukemia, T-Cell A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.	2.1	1
Kahler Disease [description not available]	2.75	3
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	7.75	3
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.05	1
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.05	1
Carcinoma, Anaplastic [description not available]	2.05	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.05	1
Weight Reduction [description not available]	2.07	1
Experimental Mammary Neoplasms [description not available]	2.07	1
Weight Loss Decrease in existing BODY WEIGHT.	2.07	1
Granulocytic Leukemia, Chronic [description not available]	2.01	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	2.01	1
Leucocythaemia [description not available]	2.01	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.01	1
Osteogenic Sarcoma [description not available]	2.02	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2.02	1
Retinal Pigment Epithelial Detachment [description not available]	2.03	1
Retinal Detachment Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).	2.03	1
Acute Myelogenous Leukemia [description not available]	2.04	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2.04	1

erucylphospho-n,n,n-trimethylpropylammonium

Description

Cross-References

Synonyms (12)

Research Excerpts

Toxicity

Compound-Compound Interactions

Bioavailability

Research

Studies (36)

Market Indicators

Research Demand Index: 11.11

Study Types

erucylphospho-n,n,n-trimethylpropylammonium

Description

Cross-References

Synonyms (12)

Research Excerpts

Toxicity

Compound-Compound Interactions

Bioavailability

Research

Studies (36)

Market Indicators

Research Demand Index: 11.11

Study Types

Related Drugs (16)

Related Conditions (55)